List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 28 studies with search of: "Medarex" [Exact]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: Treatment of metastatic melanoma
2 Active, not recruiting Study of the Combination of MDX-060 With Gemcitabine, MDX-060 Combined With Dexamethasone, and Gemcitabine Alone in Hodgkin's Disease
Condition: Hodgkin's Disease
Intervention: Drug: MDX-060 (anti-CD30 monoclonal antibody)
3 Recruiting Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Biological: MDX-1342
4 Recruiting A Dose Escalation Study of MDX-1411 to Treat Advanced or Recurrent Clear Cell Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Biological: MDX-1411
5 Active, not recruiting A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Colorectal Cancer;   Malignant Melanoma;   Renal Cancer;   Prostate Cancer
Intervention: Biological: MDX-1106
6 Recruiting A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies
Conditions: Metastatic Castration-Resistant Prostrate Cancer (mCRPC);   Renal Cell Carcinoma (RCC);   Malignant Melanoma (MEL);   Non-Small Cell Lung Cancer (NSCLC)
Intervention: Biological: MDX-1106
7 Recruiting Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: MDX-1342
8 Completed Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Biological: MDX-010
9 Recruiting Phase 1 Study of MDX-1401 in Patients With CD30-Positive Refractory/Relapsed Hodgkin's Lymphoma
Condition: Hodgkin's Lymphomas
Intervention: Biological: patients will receive active MDX-1401
10 Not yet recruiting Phase 1,Open Label,Dose-Escalation,Multidose Study in Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Mantle Cell Lymphoma (MCL)
Intervention: Drug: MDX-1411
11 Active, not recruiting MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 Melanoma Peptide Vaccine
12 Recruiting Phase 1 Open Label Study of MDX-1105 in Subjects With Solid Tumors
Conditions: Renal Cell Carcinoma;   Non-Small Cell Lung Cancer;   Malignant Melanoma;   Epithelial Ovarian Cancer
Intervention: Biological: MDX-1105
13 Completed MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Condition: Lymphoma, Large-Cell
Intervention: Drug: MDX-060
14 Recruiting A Study of MDX-1106 to Treat Patients With Hepatitis C Infection
Condition: Hepatitis C
Interventions: Drug: MDX1106-02;   Drug: Placebo
15 Completed Study of MDX-010 in Stage IV Breast Cancer
Conditions: Breast Cancer;   Adenocarcinoma
Intervention: Drug: MDX-010
16 Completed A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: MDX-1100 (anti-CXCL10 human monoclonal antibody)
17 Active, not recruiting Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Conditions: Prostate Cancer;   Neoplasm Metastasis
Intervention: Drug: MDX-010
18 Recruiting A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Biological: sterile saline for injection;   Biological: MDX-1100
19 Completed Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MDX-010 / MDX-010 + Docetaxel
20 Completed A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
Condition: Malignant Melanoma
Interventions: Drug: Ipilimumab+ Placebo;   Drug: Ipilimumab+ Budesonide

Previous Page Studies Shown (1-20) Next Page (21-28)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services